about invivo therapeutics invivo therapeutics holdings corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. the company was founded in 2005 with proprietary technology co-invented by robert langer, sc.d., professor at massachusetts institute of technology, and joseph p. vacanti, m.d., who then was at boston children’s hospital and who now is affiliated with massachusetts general hospital. in 2011, the company earned the david s. apple award from the american spinal injury association for its outstanding contribution to spinal cord injury medicine. in 2015, the company’s investigational neuro-spinal scaffold received the 2015 becker’s healthcare spine device award. the publicly-traded company is headquartered in cambridge, ma. for more details, visit www.invivotherapeutics.com. about the neuro-spinal scaffold™ following acute spinal cord injury, surgical implantation of the biodegradable neuro-spinal scaffold wi
Company profile
Ticker
NVIVQ
Exchange
Website
CEO
Richard Toselli
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Design Source, Inc.
SEC CIK
NVIVQ stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
21 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Feb 24
8-K
Bankruptcy or Receivership
1 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
3 Jan 24
ARS
2022 FY
Annual report to shareholders
5 Dec 23
DEF 14A
Definitive proxy
5 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Dec 23
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
30 Nov 23
8-K
Departure of Directors or Certain Officers
22 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
Latest ownership filings
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
4/A
Brice Foose
7 Feb 24
4
Brice Foose
7 Feb 24
SC 13G/A
Foose Brice
6 Feb 24
SC 13G
Foose Brice
25 Apr 23
3
Brice Foose
24 Apr 23
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
Lind Global Macro Fund LP
13 Feb 23
4
RICHARD CHRISTOPHER
21 Nov 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.63 mm | 8.63 mm | 8.63 mm | 8.63 mm | 8.63 mm | 8.63 mm |
Cash burn (monthly) | 746.33 k | 176.33 k | 942.67 k | 821.33 k | 760.67 k | 844.00 k |
Cash used (since last report) | 5.33 mm | 1.26 mm | 6.74 mm | 5.87 mm | 5.44 mm | 6.03 mm |
Cash remaining | 3.30 mm | 7.37 mm | 1.90 mm | 2.76 mm | 3.20 mm | 2.60 mm |
Runway (months of cash) | 4.4 | 41.8 | 2.0 | 3.4 | 4.2 | 3.1 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 1 |
Closed positions | 5 |
Increased positions | 3 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 110.39 mm |
Total shares | 3.56 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
L1 Capital Global Opportunities Master Fund | 1.06 mm | $860.00 k |
CVI Investments | 1.02 mm | $825.00 k |
Intracoastal Capital | 864.93 k | $394.00 k |
Bigger Capital Fund L P | 387.50 k | $314.00 k |
Lind Global Macro Fund | 128.32 k | $0.00 |
BLK Blackrock | 34.71 k | $46.86 mm |
Vanguard | 26.25 k | $35.43 mm |
Renaissance Technologies | 17.27 k | $23.00 k |
Geode Capital Management | 11.17 k | $15.19 mm |
Tower Research Capital | 7.39 k | $9.98 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Feb 23 | Brice Foose | InVivo Therapeutics Holdings Corp | Sell | Dispose S | No | No | 0.59 | 51,000 | 30.09 k | 0 |
6 Feb 23 | Brice Foose | InVivo Therapeutics Holdings Corp | Sell | Dispose S | No | No | 0.5 | 37,000 | 18.50 k | 51,000 |
6 Feb 23 | Brice Foose | InVivo Therapeutics Holdings Corp | Sell | Dispose S | No | No | 0.36 | 35,000 | 12.60 k | 88,000 |
6 Feb 23 | Brice Foose | InVivo Therapeutics Holdings Corp | Sell | Dispose S | No | No | 0.35 | 33,000 | 11.55 k | 123,000 |
6 Feb 23 | Brice Foose | InVivo Therapeutics Holdings Corp | Sell | Dispose S | No | No | 0.34 | 8,000 | 2.72 k | 156,000 |
5 Feb 23 | Brice Foose | InVivo Therapeutics Holdings Corp | Sell | Dispose S | No | No | 0.26 | 36,000 | 9.36 k | 164,000 |
5 Feb 23 | Brice Foose | InVivo Therapeutics Holdings Corp | Sell | Dispose S | No | No | 0.25 | 12,000 | 3.00 k | 200,000 |
5 Feb 23 | Brice Foose | InVivo Therapeutics Holdings Corp | Sell | Dispose S | No | No | 0.28 | 48,000 | 13.44 k | 212,000 |
5 Feb 23 | Brice Foose | InVivo Therapeutics Holdings Corp | Sell | Dispose S | No | No | 0.3 | 13,000 | 3.90 k | 260,000 |
5 Feb 23 | Brice Foose | InVivo Therapeutics Holdings Corp | Sell | Dispose S | No | No | 0.32 | 20,000 | 6.40 k | 273,000 |
News
12 Health Care Stocks Moving In Monday's After-Market Session
12 Feb 24
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
12 Feb 24
12 Health Care Stocks Moving In Monday's Intraday Session
12 Feb 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
8 Feb 24
Why Disney Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
8 Feb 24